BREAKING NEWS
This content is not available in your region

AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

Access to the comments Comments
AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid   -   Copyright  Brendan McDermid(Reuters)
Text size Aa Aa

(Reuters) – British drugmaker AstraZeneca Plc on Tuesday said its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission, following a panel’s consent in April.

Lynparza, being jointly developed by AstraZeneca along with U.S. drugmaker Merck & Co, can now be used in patients who are in response following chemotherapy for BRCA-mutated ovarian cancer in Europe, AstraZeneca said.

BRCA genes are responsible for producing proteins which repair damaged DNA, and if the genes are mutated, they can cause cancer growth.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Bernard Orr)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on euronews.com for a limited time.